85results about How to "Effective plasma concentration" patented technology

The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

The invention discloses a transdermal patch containing pramipexole. The transdermal patch comprises a medicine carrying pressure-sensitive adhesive layer, the pramipexole, solvent and penetration enhancer, wherein the medicine carrying pressure-sensitive adhesive layer comprises acrylate pressure-sensitive adhesive containing carboxyl base groups and acrylate pressure-sensitive adhesive containing hydroxyl base groups, which form mixed pressure-sensitive adhesive; the pramipexole is dissolved in the acrylate mixed pressure-sensitive adhesive, with the content being 10 to 30 weight percent; the content of the mixed pressure-sensitive adhesive is 50 to 80 weight percent; the content of the solvent is 5 to 20 weight percent; the content of the penetration enhancer is 2 to 15 weight percent. The pramipexole can be dissolved in a mixed pressure-sensitive adhesive patch in a high concentration way and is not crystallized, the medicine availability is high, the pramipexole has good stability in pressure-sensitive adhesive matrix, and can be continuously administrated for 5 to 7 days in a transdermal way at a relatively stable permeation rate of being larger than 5.0 micrograms/cm2/h, and the application area of a pramipexole patch is smaller than 40cm2.

The invention provides a nimodipine lipid microsphere injection, which is prepared from the following components in percentage by weight: 0.08 percent of nimodipine, 0.5 to 2.3 percent of lecithin for injection, 2 to 8 percent of soybean oil for injection, 2 to 8 percent of medium chain fatty acid for injection, 1 to 3 percent of glycerin, 0.1 to 0.2 percent of tween-80, 0.03 to 0.05 percent of sodium oleic acid, and the balance being water for injection. The preparation method comprises steps of preparation of an oil phase, preparation of water phase, preparation of colostrum, homogenization and canning. In the nimodipine lipid microsphere injection, the soybean oil for injection and the medium chain fatty acid for injection are used to prepare the oil phase, the nimodipine is a fat soluble drug and can be better dissolved in the oil phase, the lipid microsphere in which the soybean oil for injection is the main component has solvent characteristics, is non-toxic, and can guide the fat soluble drugs to be dissolved in emulsion particles and perform the metabolism along with lipid oil drops and slowly release, thereby maintaining the effective blood concentration, lowering toxic and side effects of the drugs, increasing the solubility and stability of the nimodipine drug, improving the drug-loading rate and reducing the hydrolysis of the drugs.

The invention relates to an allopurinol dual-release preparation and a preparation method thereof, which is characterized in that the dual-release preparation consists of a quick-release part and a slow-release part, wherein the ratio of the base allopurinol contained in the quick-release part to the base allopurinol contained in the slow-release part is 1:1 to 1:24. The invention belongs to the technical field of medicine preparation and aims at providing the allopurinol dual-release preparation with good patient compliance and small side effect and the preparation method thereof, wherein the allopurinol dual-release preparation has the advantages of taking effect quickly and maintaining effective blood concentration stably. The dual-release preparation can not only be used for reducing the side effect on the gastrointestinal tract, but also decreasing the administration times of a patient and adverse effect and promoting the patient compliance.

The invention relates to a diclofenac sodium hydrogel microballoon with pH sensitivity, a preparation method and application thereof. In the invention, chitosan and sodium alginate are used as drug carriers to prepare a diclofenac sodium hydrogel microballoon slow release preparation; the mass ratio of a used diclofenac sodium drug to the chitosan to the sodium alginate is (1-3):(5-8):(5-8); and the chitosan is N-succinyl-chitosan. The microballoon preparation can durably develop the drug effect to ensure that diclofenac sodium can be regularly and quantitatively released for a long time; after the microballoon preparation is taken, the blood concentration is stable, the fluctuation is small, and the duration time is long; the microballoon preparation has pH sensitivity, thereby irritations and toxic hazards to the stomach mucous membrane, which are caused by directly and orally taking diclofenac sodium tablets, are reduced; and the microballoon preparation has good effects of cooling down and easing pains and is suitable for various rheumatisms, rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, various pains caused after operations, fevers caused by various reasons, and the like.

The invention relates to oral double iguratimod controlled release formulation, which comprises fast release layer and slow release layer that are composed of 8-30% micronizing iguratimod crystal powder and medical findings, and the granule size of iguratimod crystal powder is 1-10 um. The effective component in fast release layer is released in short time and reaches to effective blood chemical concentration for effective action; the iguratimod in sloe release layer is released gradually and maintains effective blood medical concentration for continuous effective action. The invention overcomes shortcomings of short effective action time and a little high toxic effect.

The invention discloses methanesulfonic acid doxazosin controlling releasing tablets and a process for preparation, which contains a single-layer core, insoluble semi-permeable membrane, single drug-releasing eyelet on each side of the tablet, and depends on the osmotic pressure difference between inside and outside of the semi-permeable membrane medium. The invention realizes the control of linear releasing of methanesulfonic acid doxazosin by single-layer core structure, and can remain effective and steady blood and drug concentration. The curative effect is improved, the generation rate of side effect is reduced, and the productive technology is greatly simplified.

The invention relates to a nefopam hydrochloride bilayer slow-release tablet and a preparation method thereof. The nefopam hydrochloride bilayer sustained-release tablet is characterized by being prepared by the step of jointly tabletting a quick release layer and a slow release layer into a bilayer tablet, wherein the proportion of nefopam hydrochloride as the main drug contained in the quick release layer and the slow release layer is (1:1)-(1:5). The invention belongs to the technical field of medical preparations and aims at providing the nefopam hydrochloride bilayer slow-release tablet capable of relieving pain rapidly and relieving and easing pain uniformly and persistently and a preparation method thereof. The bilayer slow-release tablet has the advantages of not only decreasing side effects of a common nefopam hydrochloride preparation to the gastrointestinal tract, but also lowering the medicine-taking frequency of patients, reducing adverse effects and improving patient compliance.

The invention discloses a compound olanzapine subcutaneous implantable sustained-release preparation which comprises olanzapine and a medicinal carrier. The medicinal carrier is a controlled release agent. The invention further discloses a medicinal preparation of the compound olanzapine subcutaneous implantable sustained-release preparation, a preparation method and an application method. The compound olanzapine subcutaneous implantable sustained-release preparation disclosed by the invention has the advantages of high blood concentration stability after medicament, long time of effective effect of medicines, economical and practical benefits, convenience in delivery and the like.

The invention discloses a florfenicol premixing agent. The florfenicol premixing agent is prepared from the following raw materials in parts by weight: 2 to 3 parts of florfenicol bulk drugs, 2 to 15parts of active auxiliary materials, 2 to 10 parts of carriers, 10 to 25 parts of dissolution agent, 2 to 10 parts of stabilizer, and the balance of filling agent. The obtained florfenicol premixing agent has the advantages of high biological activity, high bioavailability, high stability, low cost, small toxicity and side effect, multiple effects and capability of promoting the growth of animals.By adopting the preparation method of the invention, the defects of a conventional complicated solid inclusion process can be avoided, the use of expensive reagent can be avoided, the process flow issimple, the cost is simple, and the preparation method has positive popularization significance.

The invention relates to a palmatine hydrochloride crystal form C as well as a preparation method thereof and an application thereof in a medicament composition or a health-care product. The invention also relates to the medicament composition or the health-care product containing a crystal, and an application of the crystal in preparing the medicament composition or the health-care product with anti-inflammation, anti-bacterium, pain alleviating and tranquilizing, anti-hypertension, cardiac arrhythmia prevention and anti-tumor effects.

The invention discloses a sustained-release tablet containing trazodone hydrochloride and a preparation method of the sustained-release tablet. The sustained-release tablet is prepared from, in percentage by weight of the whole tablet, 15%-65% of trazodone hydrochloride, 30%-85% of a sustained-release framework and 0.1%-10% of other medical auxiliaries, wherein the sustained-release framework is prepared from high-viscosity hydroxypropyl methylcellulose and water-soluble filler in the weight ratio being 1: (0.3-1.2), and other medical auxiliaries comprise a flow aid and a lubricating agent. Through matched use of high-viscosity hydroxypropyl methylcellulose and the water-soluble filler, the microporous sustained-release framework is formed; the prepared sustained-release tablet containing trazodone hydrochloride can effectively control the release speed of trazodone hydrochloride and can completely release trazodone hydrochloride contained in a sustained release tablet core within certain time, so that water-soluble trazodone hydrochloride is easily stabilized and effectively released, plasma concentration is prevented from fluctuating substantially, the prescription is simple, and the process is simple and convenient.

The invention belongs to the field of novel nanometer drugs, and discloses an esterase-responsive polycurcumin thiodipropionic acid copolymer prodrug nano-micelle, a preparation method and applications thereof, wherein the esterase-responsive polycurcumin thiodipropionic acid copolymer prodrug nano-micelle comprises, by mass, 28-93.6% of a carrier auxiliary material and 6.4-72% of a curcumin drug,the nano-micelle monomer is an amphiphilic block and comprises a hydrophilic segment and a hydrophobic segment, the hydrophilic block is methoxy polyethylene glycol with a molecular weight of 1500-6000, the hydrophobic chain segment is a curcumin poly prodrug short chain co-polymerized from thiodipropionic acid and an anticancer drug curcumin and having a molecular weight of 800-12000, and a weight ratio of the hydrophilic segment methoxypolyethylene glycol to the curcumin poly prodrug short chain is 0.1-20:1. According to the present invention, the novel nano-micelle monomer can be degradedand reduced under the action of the esterase in the cancer cells to obtain the anticancer drug curcumin bulk drug so as to achieve the precise controlled-release effect.

The invention discloses a sustained release compound capsules and its preparation method, wherein each capsule comprises a desloratadine tablet and a plurality of pseudo ephedrine slow release particles, the active components include desloratadine 2.5mg-5mg, pseudo ephedrine 120mg-240mg. The compound slow release capsule can increase the biological availability and compliableness for the patients.

Disclosed is a metronidazole double layer laminated slow release tablet comprising two layers, the first layer being a slow release layer consisting of metronidazole, slow release frame, binding agent and lubricating agent, the second layer being a quick release layer consisting of metronidazole, bulking agent, crumbling agent, binding agent and lubricating agent, wherein the mass ratio of metronidazole content in the slow release layer and in the quick release layer is 1 : 0.36-2.75. The invention also discloses the process for preparing the tablet.

The invention relates to a compound sustained-release preparation and a preparation method thereof, and the compound sustained-release preparation comprises Epristeride, terazosin hydrochloride and pharmaceutically acceptable auxiliary materials, wherein the Epristeride and the terazosin hydrochloride are used as the active components, the Epristeride is prepared into a sustained-release part, and the terazosin hydrochloride is prepared into an ordinary-release part, so that the two medicines are kept in an effective blood concentration range in vivo, the adverse effect of the medicines and the administration frequency are reduced, and the safety and effectiveness of pharmacy and the compliance of patients are improved.